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Purpose: To identify predictive factors for the incidence of total knee
replacement (TKR) during long-term follow-up of knee OA patients who
formerly received treatment with chondroitin sulfate (CS) or placebo in
a multicentre trial using clinical and quantitative magnetic resonance
imaging (qMRI) data.
Methods: Knee OA patients participating in a previous 6-month
randomized, double-blind controlled trial evaluating the impact of CS (400
mg b.i.d.; Condrosan, Bioibérica, Spain,) vs. placebo who had serial MRI
acquisitions of the symptomatic knee were recently contacted to evaluate
retrospectively the incidence of TKR of the study knee. A sub-group of
patients (n¼70) who had taken all the study medication and had all
clinical and MRI evaluations (according-to-protocol [ATP]) were selected
for this post-hoc retrospective analysis. Of this cohort 51 patients were
reachable for TKR incidence. The assessment was done blindly to treat-
ment allocation with a standardized phone interview.
Results: The patients’ mean age was 62.9 years, 61% were female and the
average BMI was 30.6 kg[[Unsupported Character - ∕]]m2. A total of 7 (6
target knees and 1 contralateral) TKRs (13.7%) were performed on this sub-
population in the timeframe of 3-4 years after completion of the original
study. Interestingly, there were more TKRs performed within the placebo
group (n¼5) than the CS group (n¼2) (71% vs. 29%, p¼0.15, logistic regres-
sion). The predictors of long-term TKRs for the target knee were investi-
gated by comparing the patients who had TKR (n¼6) of the target knee to
those who did not (n¼45), using data at baseline or the change at 1 year. At
baseline, the strongest predictors of TKR were WOMAC pain (p¼0.02,
logistic regression), stiffness (p¼0.01) and function (p¼0.04), bonemarrow
lesions of the medial tibial plateau (p¼0.03), and C reactive protein level
(p¼0.03). Changes at 1 year in medial cartilage volume (p¼0.05) and
WOMAC stiffness (p¼0.01) also predicted the occurrence of TKR.
Conclusions: These data demonstrate that, from a knee OA clinical trial, it
is possible to predict a “hard” outcome such as TKR using clinical and qMRI
data. Moreover, CS appeared to protect cartilage volume loss and improved
clinical parameters.
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COMPARISON OF ACETAMINOPHEN 1000 MG AND ACETAMINOPHEN
650 MG IN AN ACUTE PAIN MODEL: RESULTS FROM A RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY
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Purpose: Acetaminophen is recommended as a ﬁrst line treatment for
arthritis pain and 1000 mg is a widely used dose. The incremental beneﬁt
of acetaminophen 1000 mg versus 650 mg was questioned at a recent FDA
Advisory Committee Meeting. To answer this question, a randomized,
double-blind, placebo-controlled clinical trial was conducted to determine
whether acetaminophen 1000mgwasmore effective than acetaminophen
650 mg. The Dental Impaction Pain Model was chosen because of its
proven validity, assay sensitivity, reliability, and reproducibility. The
results from this model have been shown to be applicable to a wide variety
of pain modalities. The model is widely accepted and utilized to evaluate
dose-response and duration of effect of many prescription and over-the-
counter analgesics.Methods: Subjects were enrolled who required surgical extraction of up to
4 thirdmolars with aminimum requirement of 1 full bony or 2 partial bony
mandibular impactions. Subjects were randomly assigned a single dose of
acetaminophen 1000 mg, acetaminophen 650 mg, or placebo when they
had at least moderate pain and a Visual Analog Scale (VAS) score 50 out
of 100 mm post-surgically. Pain intensity and pain relief were measured
over 6 hours using a 100 mm VAS scale. Sum of Pain Intensity Difference
(SPID) and Total Pain Relief (TOTPAR) scores over 6 hours (SPRID6) was the
primary efﬁcacy endpoint. Other key efﬁcacy endpoints included Time to
Rescue analgesic, stopwatch Time to Conﬁrmed First Perceptible Relief and
Meaningful Relief, and Subject's Global Evaluation. Spontaneous adverse
events (AEs) were recorded throughout the study.
Results: All subjects (N¼540) completed the study and were included in efﬁ-
cacy and safety analyses. Demographic and baseline characteristics were
comparable among the 3 groups. Overall, the populationwas 52% female, age
16-30 years and 95% Caucasian. For the primary efﬁcacy endpoint, SPRID6,
acetaminophen 1000mg demonstrated a 24% improvement compared to 650
mg (529.4 vs 427.3; p¼0.001). Acetaminophen 1000mgwas also signiﬁcantly
superior to 650 mg (p0.002) for SPID6, TOTPAR6, Time to Rescue analgesic,
rescue rates through 4h (20% vs 32%) and 6h (29% vs 46%), and Subject Global
Evaluation (49% vs 34% with very good or excellent ratings). Both active
treatments were signiﬁcantly superior to placebo (p<0.001) for these efﬁcacy
endpoints. The 2 active treatments were similar for times to Conﬁrmed First
Perceptible andMeaningful Relief. AEswere reported by 18.5% of subjectswith
no clinically important difference among the 3 treatment groups. No serious
AEs were reported and no subjects discontinued due to an AE.
Conclusions: In this clinical trial, acetaminophen 1000 mg provided
clinically meaningful and statistically signiﬁcantly greater reduction in
pain intensity and greater pain relief compared with acetaminophen 650
mg and placebo. In addition, acetaminophen 1000 mg required less use of
rescue analgesic in treating acute pain compared with acetaminophen 650
mg and placebo. Signiﬁcantly superior efﬁcacy of acetaminophen 650 mg
was also demonstrated compared to placebo.
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A RETROSPECTIVE STUDY OF INTRA-ARTICULAR SODIUM
HYALURONATE (MW 500-730 KDA) INJECTION FOR TRAPEZIO-
METACARPAL JOINT OSTEOARTHRITIS
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Purpose: Hand osteoarthritis (OA) is a highly prevalent disease, and TMCJ
is commonly targeted by OA. With respect to the long-term results, Hya-
luronic Acid (HA) seems to be the better alternative in the treatment of
TMCJ OA, even with a single injection. HA injections were found to be
effective in reducing pain and improving ﬁne hand function.
The purpose of this retrospective open-label study was to evaluate the
efﬁcacy and tolerability of i.a. injections of HA for the treatment of pain and
disability due to TMCJ OA. Data from the study were discussed based on
a review of the current news on the physiological effects of HA.
Methods: Fifty-eight patients, 50W(86.2%) and8M (13.8%), agedbetween40-
75ys, suffering fromTMCJOAandclassiﬁedasK-Lgrades2-3asper standardX-
ray, were included. The cases with known inﬂammatory arthritis, previous
thumb trauma and intra-articular (i.a.) injections with corticosteroids were
excluded. Primaryendpointswere:pain (VAS),NSAID intake, radial andpalmar
abduction of thumb (degrees), pinch strength (Kg/hand dynamometer).
Between Jan. 2000andDec. 2002 thepatients receivedan i.a. injectionof 0.8ml
of Hyaluronan saline, Hyalgan (10 mg/ml, MW 500-730 KDa)once weekly for
three consecutive weeks, using a dorsolateral approach. Control examinations
were carried out one, three and six months after the ﬁrst treatment.
Results: Intra-articular HA injections signiﬁcantly reduced spontaneous
and provoked pain and improved hand function and motion range in
comparison with baseline values. In particular after 1, 3 and 6 months
following the ﬁrst injection, the spontaneous and provoked pain revealed
a statistically signiﬁcant improvement (p<0,0001). In addition hand
functionality, in particular pinch strength, showed a signiﬁcant improve-
ment after the treatment. NSAIDs intake also evidenced a statistically
signiﬁcant reduction against baseline (p<0,017). The adverse events
occurring during the study (20.7%) are expected and related to local
symptoms such as pain during or following the HA administration.
